ROIV Stock Price Today (April 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-04-02
Roivant Sciences Ltd. (ROIV) is trading at $28.43, up 2.10% today (as of April 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $33.25 (17.0% upside).
- Volatility remains elevated (27.86% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-77.80% YoY) alongside significant competitive pressures.
ROIV Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $16.56B
P/E Ratio
Forward P/E: -27.46
Revenue Growth
Year over Year
Analyst Target
+17.0% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 58.23)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $108.94M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $8.73 and $30.33—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.86% annualized volatility and β=1.21, the stock exhibits high sensitivity to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January 2021 as high as $175, when it was the height of the pandemic. Since then, it has dropped as much as ... This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?
Roivant Sciences recently reported past topline Phase 3 results showing that Immunovant’s batoclimab did not meet the primary endpoint in thyroid eye disease, while also announcing that Priovant has begun a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, alongside ongoing late-stage programs and an FDA Priority Review for dermatomyositis. This mix of pipeline expansion into an underserved inflammatory scalp disorder with no approved therapies, coupled with regulatory...
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expand
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint
Roivant Sciences (NASDAQ:ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brepocitinib into lichen planopilaris (LPP) and provided an update on a Phase III thyroid eye disease (TED) trial for batoclimab during a conference call hosted by the company. Brepocitinib expands into l
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target, citing potential upside from upcoming clinical readouts in pulmonary hypertension associated with interstitial lung disease and […]
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more locations and adds vision services, investors are paying attention to whether its strong brand can drive lasting growth.
Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement
Moderna settled a yearslong patent dispute with Arbutus Biopharma and Roivant. Moderna stock jumped Wednesday.
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength
Roivant Sciences snapshot after recent performance Roivant Sciences (ROIV) has drawn fresh attention after a strong share price move, with the stock showing gains over the past month and past 3 months that stand out against its longer term record. See our latest analysis for Roivant Sciences. With the share price at US$27.85, Roivant Sciences has recently posted a 28.82% 1 month share price return and a 34.54% 3 month share price return. Its 1 year total shareholder return of 169.86% points...
Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock.
The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $28.43. The RSI (14-day) is at 58.2, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $33.25 implies 17.0% upside from current levels. Volatility is moderate at 27.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -27.46. Price-to-Book is 4.71. Price-to-Sales is 1523.35. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ROIV, the consensus price target is $33.25. This represents a 17.0% upside from the current price of $28.43. The range spans from a low target of $22.00 to a high target of $39.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. Moderate volatility (27.9% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-77.8% YoY), indicating potential business headwinds. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $108.94M. The debt-to-equity ratio is 2.19, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 30.66, indicating strong short-term liquidity. The quick ratio is 29.81. The company holds $4.53B in cash and equivalents. Free cash flow is negative at $-334,342,944, which could limit the company's ability to manage debt obligations.